-----------------------------
OMB APPROVAL
-----------------------------
OMB Number 3235-0145
Expires: December 31, 2005
Estimated average burden
hours per response ..... 11
-----------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Bentley Pharmaceuticals, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $.02 per share
--------------------------------------------------------------------------------
(Title of Class of Securities)
082657 10 7
------------------------------------------------------------------------------
(CUSIP Number)
December 31, 2002
-----------------------------------------------------------
(Date of Event which requires filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Statement
is filed:
[ ] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[X] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 5 Pages
CUSIP No. 082657 10 7 13G Page 2 of 5 Pages
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
James R. Murphy
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
5 SOLE VOTING POWER
NUMBER OF 977,363
SHARES -------------------------------------------------------------
BENEFICIALLY
OWNED BY 6 SHARED VOTING POWER
EACH 0
REPORTING -------------------------------------------------------------
PERSON 7 SOLE DISPOSITIVE POWER
WITH
977,363
-------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
0
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
977,363
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[X]
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
5.3%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
IN
--------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT
CUSIP No. 082657 10 7 13G Page 3 of 5 Pages
--------------------------------------------------------------------------------
Item 1(a) NAME OF ISSUER:
Bentley Pharmaceuticals, Inc.
Item 1(b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
65 Lafayette Road, Third Floor
North Hampton, NH 03862
Item 2(a) NAME OF PERSON FILING:
James R. Murphy
Item 2(b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
65 Lafayette Road, Third Floor
North Hampton, NH 03862
Item 2(c) CITIZENSHIP:
United States
Item 2(d) TITLE OF CLASS OF SECURITIES:
Common Stock, par value $.02
Item 2(e) CUSIP NUMBER:
082657 10 7
Item 3 IF THIS STATEMENT IS FILED PURSUANT TO 240.13d-1(b) or
240.13d-2(b) or (c):
Not applicable.
Item 4 OWNERSHIP:
(a) Amount Beneficially Owned: 977,363 shares*
(b) Percent of Class: 5.3%
(c) Number of shares as to which the person has:
i. sole power to vote or to direct the vote:
977,363 shares*
ii. shared power to vote or direct the vote: 0
CUSIP No. 082657 10 7 13G Page 4 of 5 Pages
--------------------------------------------------------------------------------
iii. sole power to dispose or to direct the
disposition of: 977,363 shares*
iv. shared power to dispose or to direct the
disposition of: 0
* includes 100 shares owned by Reporting
Person's son, as to which Reporting Person
disclaims beneficial ownership; also includes
854,500 shares issuable upon the exercise of
warrants and options which are exercisable
within 60 days but are not currently outstanding
Item 5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
Not applicable.
Item 6 OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
Not applicable.
Item 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH
ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING
COMPANY:
Not applicable.
Item 8 IDENTIFICATION AND CLASSIFICATION OF MEMBER OF THE GROUP:
Not applicable.
Item 9 NOTICE OF DISSOLUTION OF GROUP:
Not applicable.
Item 10 CERTIFICATION:
Not applicable.
CUSIP No. 082657 10 7 13G Page 5 of 5 Pages
--------------------------------------------------------------------------------
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
February 14, 2003
----------------------------------
Date
/S/ JAMES R. MURPHY
----------------------------------
Signature
James R. Murphy
----------------------------------
Name/Title